AS
Highly rated in
64
conditions

Dr. Alexander I. Spira

Virginia Cancer Specialists, P.C.
Fairfax, VA
Highly rated in
64
conditions
Specialties:Oncology | Hematology Oncology | Hematology
Experience:26 Years
Clinical Trials:Currently Recruiting for 29 Trials
Accepts:New PatientsMedicare
Highly rated in
64
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Alexander I. Spira's experience treating your condition:
About Dr. Alexander I. Spira

Alexander Spira is an Oncologist and a Hematologist Oncology expert in Fairfax, Virginia. Spira has been practicing medicine for over 26 years and is highly rated in 64 conditions, according to our data. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, Tissue Biopsy, and Orchiectomy. He is licensed to treat patients in Virginia. Spira is currently accepting new patients.

His clinical research consists of co-authoring 98 peer reviewed articles and participating in 99 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Alexander I. Spira it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Alexander I. Spira accepts the following insurance:

  •  Ambetter
  •  Cigna
  •  CareFirst
  •  HealthKeepers
  •  Optima Health
  •  Innovation Health
Call to see if your plan is accepted.
Locations
8613 Lee Hwy # 200n, Fairfax, VA 22031
Other Locations
1860 Town Center Dr, Suite 460, Reston, VA 20190
10301 Democracy Ln, Fairfax, VA 22030
Background & Education
Graduate Institution
New York University School Of Medicine, 1997
Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in VA
Hospital Affiliations
Henrico Doctors Hospital
Prince William Medical Center
Inova Fair Oaks Hospital
Sentara Northern Virginia Medical Center
Haymarket Medical Center
Reston Hospital Center
Inova Alexandria Hospital
VHC Health
Inova Fairfax Hospital
Languages Spoken
English
Farsi
French
Spanish
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

95 Clinical Trials
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: February 03, 2022
Intervention Type: Drug
Study Drug: INBRX-105 PDL1x41BB Antibody
Study Phase: Phase 1
A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST).
Enrollment Status: Recruiting
Publish Date: November 17, 2022
Intervention Type: Biological
Study Phase: Phase 1
Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies
Enrollment Status: Recruiting
Publish Date: August 17, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of VS-6766 in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Drug
Study Drugs: SEA-TGTPembrolizumab
Study Phase: Phase 1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Recruiting
Publish Date: December 21, 2021
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 05, 2022
Intervention Type: Drug
Study Drug: Surufatinib+Tislelizumab
Study Phase: Phase 1/Phase 2
Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Drug
Study Drugs: SAR408701PembrolizumabCisplatinCarboplatin
Study Phase: Phase 2
An Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 21, 2022
Intervention Type: Drug
Study Phase: Phase 1
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Enrollment Status: Recruiting
Publish Date: November 22, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Enrollment Status: Recruiting
Publish Date: August 03, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 06, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Subjects With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: November 04, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes
Enrollment Status: Recruiting
Publish Date: December 07, 2022
Intervention Type: Drug
Study Drug: Nab-sirolimus
Study Phase: Phase 2
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: November 22, 2022
Intervention Type: Drug
Study Drug: ASTX295
Study Phase: Phase 1/Phase 2
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Recruiting
Publish Date: September 16, 2022
Intervention Type: Drug
Study Drugs: VS-6766Defactinib
Study Phase: Phase 2
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies
Enrollment Status: Recruiting
Publish Date: November 18, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 Monotherapy and XTX101 and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 01, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: December 23, 2021
Intervention Type: Drug
Study Drug: NBF-006
Study Phase: Phase 1
A First-In-Human, Phase 1 a/b Dose Escalation and Expansion Study to Evaluate RBS2418 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Unresectable, Recurrent or Metastatic Tumors
Enrollment Status: Recruiting
Publish Date: October 13, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Enrollment Status: Recruiting
Publish Date: November 28, 2022
Intervention Type: Drug
Study Drugs: TucatinibTrastuzumabFulvestrant
Study Phase: Phase 2
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With Advanced Malignancies Associated With EphA2 Expression
Enrollment Status: Recruiting
Publish Date: November 21, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: November 22, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Drug
Study Drugs: TSR-022NivolumabTSR-042TSR-033Docetaxel
Study Phase: Phase 1
Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N)
Enrollment Status: Recruiting
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drug: Capmatinib
Study Phase: Phase 2
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Recruiting
Publish Date: April 04, 2022
Intervention Type: Drug
Study Drugs: BrigatinibAlectinib
Study Phase: Phase 3
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: December 01, 2022
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 12, 2022
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase 1b/Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: May 02, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 With Osimertinib in Participants With EGFR Mutation Positive, Locally Advanced or Metastatic NSCLC
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Drug
Study Drugs: RMC-4630CobimetinibOsimertinib
Study Phase: Phase 1/Phase 2
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 13, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
Enrollment Status: Active, not recruiting
Publish Date: November 09, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy
Enrollment Status: Completed
Publish Date: June 23, 2022
Intervention Type: Drug
Study Drugs: RamucirumabNecitumumabOsimertinib
Study Phase: Phase 1
Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma
Enrollment Status: Active, not recruiting
Publish Date: November 14, 2022
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Available
Publish Date: December 08, 2022
Intervention Type: Drug
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Active, not recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
Study Drugs: ZimberelimabDomvanalimabEtrumadenant
Study Phase: Phase 2
A Multi-Center, Phase Ib/II Study of Combination Treatment of APG-1252 With Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 12, 2022
Intervention Type: Drug
Study Drugs: APG-1252Paclitaxel
Study Phase: Phase 1/Phase 2
A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
Enrollment Status: Active, not recruiting
Publish Date: September 23, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
Enrollment Status: Active, not recruiting
Publish Date: April 06, 2022
Intervention Type: Drug
Study Drug: TP-0903
Study Phase: Phase 1
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Enrollment Status: Terminated
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active, not recruiting
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Enrollment Status: Active, not recruiting
Publish Date: February 21, 2022
Intervention Type: Drug, Biological
Study Drugs: Galinpepimut-SPembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Active, not recruiting
Publish Date: December 14, 2022
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Enrollment Status: Active, not recruiting
Publish Date: August 03, 2022
Intervention Type: Drug
Study Drugs: CPI-006 Anti-CD73 AntibodyCiforadenantPembrolizumab
Study Phase: Phase 1
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Enrollment Status: Unknown status
Publish Date: November 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Drug
Study Drugs: ItacitinibOsimertinib
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients With Surgically Resectable Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: January 11, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 21 Less Clinical Trials -
98 Total Publications
Adagrasib in Non-Small-Cell Lung Cancer. Reply.
Journal: The New England journal of medicine
Published: September 28, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
CK
Dr. Craig M. Kessler
Hematology Oncology | Hematology | Oncology
Highly rated in
34
conditions
Hematology Oncology
Hematology
Oncology

MedStar Health

MedStar Georgetown University Hospital

3800 Reservoir Rd Nw, 
Washington, DC 
 9.4 mi

Craig Kessler is a Hematologist Oncology specialist and a Hematologist in Washington, Washington, D.c.. Kessler has been practicing medicine for over 50 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in District of Columbia. Kessler is currently accepting new patients.

BL
Dr. Benjamin P. Levy
Oncology | Hematology Oncology | Hematology
Highly rated in
10
conditions
Oncology
Hematology Oncology
Hematology

Johns Hopkins Health System

Sibley Memorial Hospital

5255 Loughboro Rd Nw, 
Washington, DC 
 8.4 mi

Benjamin Levy is an Oncologist and a Hematologist Oncology expert in Washington, Washington, D.c.. Levy has been practicing medicine for over 21 years and is highly rated in 10 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. He is licensed to treat patients in Maryland and New York. Levy is currently accepting new patients.

RB
Dr. Robert A. Brodsky
Hematology | Oncology
Highly rated in
31
conditions
Hematology
Oncology

Johns Hopkins Health System

Johns Hopkins University

600 N Wolfe St, 
Baltimore, MD 
 45.6 mi

Robert Brodsky is a Hematologist and an Oncologist in Baltimore, Maryland. Brodsky has been practicing medicine for over 34 years and is highly rated in 31 conditions, according to our data. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, Anemia, and Bone Marrow Transplant. He is licensed to treat patients in Maryland. Brodsky is currently accepting new patients.